eligibility_summary
Adults 18–80 with newly diagnosed DLBCL who consent, ECOG 0–2, ≥3‑month survival, measurable disease (LN >1.5 cm or extranodal >1.0 cm), adequate marrow/renal/hepatic function, and acceptable cardiac status (LVEF ≥50% or >55% with controlled CV disease). Exclude drug allergy, uncontrolled illness, major cardiac risks (e.g., QTc>480 ms), active HBV/HCV, HIV, other active cancers, CNS lymphoma, pregnancy/lactation, or otherwise unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Single-arm trial of R-CMOP for newly diagnosed DLBCL with cardiac-function screening. Regimen and mechanisms: Rituximab (chimeric anti-CD20 monoclonal antibody, depletes B cells via complement, ADCC, and apoptosis). Cyclophosphamide (alkylating agent, DNA crosslinking causing cell death). Mitoxantrone hydrochloride liposome (liposomal anthracenedione/topoisomerase II inhibitor, DNA intercalation/Topo II inhibition with reduced cardiotoxicity). Vincristine or Vindesine (vinca alkaloid mitotic inhibitors, bind tubulin to block microtubule polymerization). Prednisone (glucocorticoid, induces lymphoid apoptosis, anti-inflammatory). Targets/pathways: CD20+ B cells, DNA damage/Topo II, microtubule dynamics, glucocorticoid receptor signaling, immune effector pathways (ADCC/complement). Aim: efficacy/safety while limiting cardiotoxicity.